Physician profile
Brent A Baker
NPI 1003270968
$1,869.20
in general payments reported to CMS, 2019-2025
20 companies · $1,111 in 2025
The $1,111 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.22 · 2022: $69.14 · 2023: $147 · 2024: $494 · 2025: $1,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,751.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $572.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Heartflow, INC. | $228.90 | 2025 | |
| Pfizer INC. | $209.80 | 2024-2025 | |
| Abbvie INC. | $188.35 | 2024-2025 | |
| Glaxosmithkline, LLC. | $148.15 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Dexcom, INC. | $101.35 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $71.39 | 2025 | Airsupra, Farxiga |
| Sequel Med Tech, LLC | $58.77 | 2025 | Twiist |
| Bayer Healthcare Pharmaceuticals INC. | $36.61 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.54 | 2025 | Jardiance |
| Corcept Therapeutics | $30.00 | 2025 | Korlym |
| Medtronic, INC. | $27.34 | 2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $26.62 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Astellas Pharma US INC | $25.64 | 2025 | Veozah |
| Insulet Corporation | $23.54 | 2025 | Omnipod |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $21.49 | 2025 | Trintellix |
| Axsome Therapeutics, INC. | $19.05 | 2025 | Auvelity |
| Amphastar Pharmaceuticals, INC. | $16.77 | 2025 | |
| Novartis Pharmaceuticals Corporation | $15.23 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $14.43 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.